e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Single centre experience with endothelin receptor blockade in pulmonary hypertension
I. J. Armstrong, C. A. Elliot, R. Barraclough, C. Billings, J. Waterhouse, L. O‘Toole, E. A. Taylor, D. G. Kiely (Sheffield, United Kingdom)
Source:
Annual Congress 2004 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Oral Presentation
Number:
136
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. J. Armstrong, C. A. Elliot, R. Barraclough, C. Billings, J. Waterhouse, L. O‘Toole, E. A. Taylor, D. G. Kiely (Sheffield, United Kingdom). Single centre experience with endothelin receptor blockade in pulmonary hypertension. Eur Respir J 2004; 24: Suppl. 48, 136
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
Endothelin: setting the scene in PAH
Source: Eur Respir Rev 2008; 17: 3-7
Year: 2007
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Inhalation of endothelin receptor blockers in pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Dual endothelin receptor blockade: advances in pulmonary disease
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Source: Eur Respir Rev 2009; 18: 253-259
Year: 2009
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 204s
Year: 2005
Bosentan therapy for portopulmonary hypertension
Source: Eur Respir J 2005; 25: 502-508
Year: 2005
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept